NR3C2 and heart failure: Despite abundant preclinical and mechanistic data supporting the concept, no clinically meaningful benefit, i.e., reduction in overall or cardiovascular mortality, ventricular arrhythmia, or rehospitalization, with use of MR antagonists in early post-MI patients without evidence of heart failure has been demonstrated in major prospective randomized clinical trials (44, 45).